The Food and Drug Administration (FDA) is due to decide on Monday whether to approve Biogen’s aducanumab drug for use in the US, according to Sky News.
Aducanumab targets amyloid – plaque that builds up in the brains of people with Alzheimer’s – helping to slow the onset of the condition.
It is the first treatment to target the cause of the disease, as existing ones only help to ease symptoms.
According to The Times of Israel, The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide, for long-term weight management.
In company-funded studies, participants taking Wegovy had average weight loss of 15%, about 34 pounds (15.3 kilograms).
Participants lost weight steadily for 14 months before plateauing.
Writing for The Times, Kat Lay said The US Food and Drugs Administration (FDA) said the company Biogen could market the drug, called aducanumab, in the United States, but that it would need to complete a further large clinical trial to confirm its benefit to patients.
Regulators in Europe and the UK are not expected to make any ruling until the autumn but the US decision was hailed as promising by British campaigners.
Professor Bart De Strooper, the director of the UK Dementia Research Institute, said: “With no effective therapies currently available to modify the progression of this devastating condition, this is a major milestone for the millions of people living with Alzheimer’s.”.
He warned however that “controversy and uncertainty” surrounding trials of the drug might limit the impact of the new treatment.